GO
Loading...

Enter multiple symbols separated by commas

Pfizer Inc

More

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • GlaxoSmithKline opts to hold on to HIV business Wednesday, 6 May 2015 | 8:14 AM ET

    LONDON— British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis. Those deals included GSK's sale of its cancer-drug business to Novartis in a swap for the Swiss company's vaccines business and cash. GSK said it would reduce a planned...

  • May 5- Animal health products maker Zoetis Inc said it plans to cut up to a quarter of its workforce and exit nearly 40 percent of its manufacturing plants in its first major restructuring since being spun off from Pfizer Inc two years ago. The restructuring comes a month after activist investor Pershing Square seated their second nominee on Zoetis's board in...

  • May 5- Animal health products maker Zoetis Inc said it would reduce operations in Venezuela and consider selling or exiting 10 manufacturing sites over the long term. Ackman's Pershing Square Capital Management was Zoetis's biggest shareholder with an 8.35 percent stake as of April 10, according to Thomson Reuters data. Zoetis, which was spun off from Pfizer...

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • NEW YORK/ LONDON, April 30- Pfizer Inc is the mystery bidder for Swedish Orphan Biovitrum AB, the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer, people with knowledge of the situation said. Sobi did not identify its potential acquirer when it revealed on Monday that it had received an approach, but Biogen and...

  • Final Glance: Pharmaceuticals companies Wednesday, 29 Apr 2015 | 6:14 PM ET

    Baxter International Inc. fell$. 48 or. 7 percent, to $69.75. Bristol-Myers Squibb Co. fell$. 25 or. 4 percent, to $64.29. Eli Lilly& Co. rose $1.10 or 1.5 percent, to $72.28.

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks traded lower as investors weighed a weaker-than-expected GDP report and earnings reports ahead of the Fed statement release.

  • Midday Glance: Pharmaceuticals companies Wednesday, 29 Apr 2015 | 2:53 PM ET

    Baxter International Inc. fell$. 50 or. 7 percent, to $69.74. Bristol-Myers Squibb Co. fell$. 56 or. 9 percent, to $63.98. Eli Lilly& Co. rose$. 97 or 1.4 percent, to $72.15.

  • Most active New York Stock Exchange-traded stocks Wednesday, 29 Apr 2015 | 2:53 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AT&T Inc. fell. 3 percent to $34.76 with 39,838,600 shares traded. Bank of America Corp. rose 2.1 percent to $15.98 with 122,945,200 shares traded.

  • Dust off the weak economy trade: 5 buys Wednesday, 29 Apr 2015 | 12:23 PM ET
    Traders work the floor of the New York Stock Exchange.

    U.S. GDP figures stalled last quarter, setting up a winning short-term trade in certain sectors and slices of the stock market.

  • Early Glance: Pharmaceuticals companies Wednesday, 29 Apr 2015 | 10:45 AM ET

    Baxter International Inc. fell$. 31 or. 4 percent, to $69.92. Bristol-Myers Squibb Co. rose$. 19 or. 3 percent, to $64.73. Eli Lilly& Co. rose $1.00 or 1.4 percent, to $72.18.

  • Final Glance: Pharmaceuticals companies Tuesday, 28 Apr 2015 | 6:04 PM ET

    Baxter International Inc. fell$. 14 or. 2 percent, to $70.23. Bristol-Myers Squibb Co. fell$. 62 or 1.0 percent, to $64.54. Eli Lilly& Co. rose$. 29 or. 4 percent, to $71.18.

  • Pfizer Inc., Merck& Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their revenue from selling products overseas. Pfizer cut its 2015 earnings-per-share forecast by a nickel, to between $1.95 and $2.05, in the face of two fierce headwinds. New York- based Pfizer said those two factors will reduce 2015...

  • Traders work on the floor of the New York Stock Exchange.

    U.S.stocks closed mixed on Tuesday as investors eyed tech earnings and awaited the Federal Reserve's statement on Wednesday.

  • Most active New York Stock Exchange-traded stocks Tuesday, 28 Apr 2015 | 1:51 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AK Steel Holding Corp. rose 9.4 percent to $5.35 with 22,809,400 shares traded. AT&T Inc. rose 2.3 percent to $34.86 with 48,346,300 shares traded.

  • Midday Glance: Pharmaceuticals companies Tuesday, 28 Apr 2015 | 1:50 PM ET

    Baxter International Inc. fell$. 13 or. 2 percent, to $70.24. Bristol-Myers Squibb Co. fell$. 87 or 1.3 percent, to $64.29. Eli Lilly& Co. rose$. 29 or. 4 percent, to $71.18.

  • NEW YORK, April 28- A federal judge dismissed claims by former Elan Corp and Wyeth shareholders accusing billionaire investor Steven A. Cohen's SAC Capital Advisors LP of violating federal racketeering law by conducting insider trading in the drugmakers' stocks. District Judge Victor Marrero in Manhattan said the civil claims brought under the Racketeer...

  • Early Glance: Pharmaceuticals companies Tuesday, 28 Apr 2015 | 10:39 AM ET

    Baxter International Inc. fell$. 48 or. 7 percent, to $69.89. Bristol-Myers Squibb Co. fell $1.39 or 2.1 percent, to $63.77. Eli Lilly& Co. fell$. 20 or. 3 percent, to $70.70.

  • US STOCKS-Wall St fall as earnings disappoint Tuesday, 28 Apr 2015 | 10:13 AM ET

    *Merck on track for its best day since January 2014. Apple hit a record high before falling as much as 1.7 percent to $130.33 despite beating Wall Street's revenue and profit forecasts. Merck rose 4.8 percent to $59.85, on track for its best day since January 2014, after its diabetes drug, Januvia, achieved the main goal in a safety study.